NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to ...

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Jim Herlihy, a regional spokesman for the Alzheimer’s Association, will tell you that Kocherhans finds himself in good, if ...

Leqembi (lecanemab-irmb) is a prescription drug that’s used to treat Alzheimer’s disease. It comes as a liquid solution that healthcare professionals administer as an intravenous (IV ...

Leqembi (lecanemab-irmb) has potential interactions with other medications. These interactions could cause harmful effects. An interaction can occur because one substance causes another substance ...

The study results on Leqembi, which Eisai shares with Biogen, also found that a patient's Alzheimer's disease worsens after they stop treatment. Rates of adverse side effects associated with ...

That eventually made her a good fit for Leqembi, which won regulatory approval in the U.S. in July 2023. Get local news you need to know to start your day with NBC 6's News Headlines newsletter.